Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee

Transcript

BY ABOUT THE SAME AMOUNT. BUT ATTENTION IS SHIFTING TO NEW COMPETITORS IN THE SPACE, WITH AMGEN SET TO RELEASE A NEW DATA OR SOME NEW DATA ON ITS MONTHLY OBESITY SHOT BEFORE YEAR END. OUR NEXT GUEST SAYS POTENTIALLY STRONG DATA COULD PUT PRESSURE ON LILLY SHARES. FOR MORE, LET'S BRING IN CAPITAL MANAGING DIRECTOR LEN LEN, GREAT TO HAVE YOU WITH US.... Read More